-
41
-
42
Update from Canadian Respirology Program Directors
Published 2004-01-01“…Submitted by Elizabeth Tullis MD FRCPC Associate Professor of Medicine, Respirology Program Director, University of Toronto, Toronto, Ontario The Canadian Organization of Pulmonary Program Directors (COPPD) had their first meeting in Montreal on November 7, 2003, which was sponsored by an unrestricted educational grant from AstraZeneca Canada Inc. This meeting was held in conjunction with the Royal College of Physicians and Surgeons (RCPS) Respirology Subspecialty Committee meeting held on November 6, 2003, and with the first Canadian Division Directors meeting held on November 8, 2003.…”
Get full text
Article -
43
-
44
-
45
-
46
Asthma Control in Canada Remains Suboptimal: The Reality of Asthma Control (TRAC) Study
Published 2006-01-01Get full text
Article -
47
-
48
-
49
IL-33 Mediates Lung Inflammation by the IL-6-Type Cytokine Oncostatin M
Published 2020-01-01Get full text
Article -
50
A Descriptive-Multivariate Analysis of Community Knowledge, Confidence, and Trust in COVID-19 Clinical Trials among Healthcare Workers in Uganda
Published 2023“…We also found a high level of skepticism and possible community resistance to DNA recombinant vaccines, such as the Oxford–AstraZeneca vaccine. Preference for herbal treatments (38/260; 14.6%, 95% CI: 10.7–19.3) currently being promoted by the Ugandan government raises major policy concerns. …”
Get full text
Article -
51
COVID-19 Booster Vaccines Administration in Different Countries
Published 2021-12-01“…This includes COVID-19 vaccines by Pfizer-BioNTech, Moderna, AstraZeneca, Janssen, Sinovac, and Sinopharm. Findings suggested that protection against COVID-19 provided by these vaccines may be waning or that the protection reduces against variants of concern (VOC) or even inadequate protection of the primary vaccination for some risk groups. …”
Get full text
Article -
52
Metyrapone for Long-Term Medical Management of Cushing’s Syndrome
Published 2013-01-01Get full text
Article -
53
Manifestaciones neurológicas asociadas a la vacuna contra COVID-19
Published 2025-01-01“…La mayoría de casos publicados se produjeron en asociación temporal con la vacuna Pfizer (BNT162b2), seguida de la vacuna de AstraZeneca (ChAdOX1 nCoV-19). Conclusiones: Con los datos existentes actualmente no es posible establecer una relación de causalidad entre estos eventos adversos y las vacunas contra la COVID-19, ni calcular la frecuencia de aparición de estos trastornos. …”
Get full text
Article -
54
Neurological manifestations associated with COVID-19 vaccine
Published 2025-01-01“…Most of the published cases occurred in temporal association with the Pfizer vaccine (BNT162b2), followed by the AstraZeneca vaccine (ChAdOX1-S). Conclusions: It is not possible to establish a causal relationship between these adverse events and COVID-19 vaccines with the currently existing data, nor to calculate the frequency of appearance of these disorders. …”
Get full text
Article -
55
-
56
-
57
Anti-SARS-CoV-2 Antibody Level among Renal Transplant Recipients: A Case Report from Nepal
Published 2022-01-01“…All three cases had received two doses of Oxford-AstraZeneca COVID-19 vaccine AZD1222 (ChAdOx1). Serological analysis showed protective level of circulating antibodies in the blood of all three cases. …”
Get full text
Article -
58
-
59
A bad dream come true: ICT patent prosecution against EU competition law
Published 2022-11-01“…Regarding Art. 102 TFEU, the article concludes that the AstraZeneca jurisprudence on abusive patent prosecution is of a limited application for anti-competitive ICT patenting practices that essentially concern blocking patents. …”
Get full text
Article -
60